ישראל - עברית - Ministry of Health

astrazeneca (israel) ltd - exenatide - אבקה וממס להכנת תרחיף להזרקה - exenatide 2 mg - exenatide - exenatide - bydureon is indicated for treatment of type 2 diabetes mellitus in combination with : • metformin• sulphonylurea• metformin and sulphonylureain adults who have not achieved adequate glycaemic control on maximally tolerated doses of these oral therapies.

ישראל - עברית - Ministry of Health

vitamed pharmaceutical industries ltd - diclofenac sodium - ג'ל - diclofenac sodium 1 %w/w - diclofenac - diclofenac - local treatment of rheumatic diseases, non infected inflammations and pain.

ישראל - עברית - Ministry of Health

נגרין סופיה - הזנת העור

ישראל - עברית - Ministry of Health

teva pharmaceutical indust.ltd - metformin hydrochloride 850 mg - tablets - metformin - metformin teva is indicated in diet - failed non - insulin dependent diabetic patients especially if overweight either alone as initial therapy or in combination with a sulfonylurea. occasionally as adjuvant therapy in insulin - dependent diabetic patients particularly who are usually obese and not well controlled with insulin.

ישראל - עברית - Ministry of Health

teva pharmaceutical indust.ltd - metformin hydrochloride 850 mg - tablets - metformin - metformin teva is indicated in diet - failed non - insulin dependent diabetic patients especially if overweight either alone as initial therapy or in combination with a sulfonylurea. occasionally as adjuvant therapy in insulin - dependent diabetic patients particularly who are usually obese and not well controlled with insulin.

ישראל - עברית - Ministry of Health

teva pharmaceutical indust.ltd - metformin hydrochloride 850 mg - tablets - metformin - metformin teva is indicated in diet - failed non - insulin dependent diabetic patients especially if overweight either alone as initial therapy or in combination with a sulfonylurea. occasionally as adjuvant therapy in insulin - dependent diabetic patients particularly who are usually obese and not well controlled with insulin.

ישראל - עברית - Ministry of Health

teva pharmaceutical indust.ltd - metformin hydrochloride 850 mg - tablets - metformin - metformin teva is indicated in diet - failed non - insulin dependent diabetic patients especially if overweight either alone as initial therapy or in combination with a sulfonylurea. occasionally as adjuvant therapy in insulin - dependent diabetic patients particularly who are usually obese and not well controlled with insulin.

ישראל - עברית - Ministry of Health

teva pharmaceutical indust.ltd - metformin hydrochloride 850 mg - tablets - metformin - metformin teva is indicated in diet - failed non - insulin dependent diabetic patients especially if overweight either alone as initial therapy or in combination with a sulfonylurea. occasionally as adjuvant therapy in insulin - dependent diabetic patients particularly who are usually obese and not well controlled with insulin.

ישראל - עברית - Ministry of Health

teva pharmaceutical indust.ltd - metformin hydrochloride 850 mg - tablets - metformin - metformin teva is indicated in diet - failed non - insulin dependent diabetic patients especially if overweight either alone as initial therapy or in combination with a sulfonylurea. occasionally as adjuvant therapy in insulin - dependent diabetic patients particularly who are usually obese and not well controlled with insulin.

ישראל - עברית - Ministry of Health

astrazeneca (israel) ltd - saxagliptin as hydrochloride - טבליות מצופות פילם - saxagliptin as hydrochloride 5 mg - saxagliptin - saxagliptin - monotherapy: onglyza is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.onglyza should not be used in patients with esrdcombination therapy: add-on combination: onglyza is indicated in patients with type 2 diabetes mellitus to improve glycemic control in combination with metformin, a thiazolidinedione (tzd), or a sulfonylurea (su), when the single agent alone, with diet and exercise, does not provide adequate glycemic control.initial combination: onglyza is indicated for use as initial combination therapy with metformin, as an adjunct to diet and exercise, to improve glycemic control in patients with type 2 diabetes mellitus when dual saxagliptin and metformin therapy is appropriate.onglyza should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. in combination with insulin (with or without metformin), when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.